

SENATE BILL 2762 (MORRISON-BRYANT)

SB 2762 amends the Illinois Insurance Code and the Illinois Public Aid Code to provide coverage for medically prescribed, FDA-cleared seizure detection and monitoring devices.

Approximately 30% of people with epilepsy experience tonic-clonic seizures according to the American Epilepsy Society. A tonic-clonic (formerly grand mal) seizure is a severe type of epileptic seizure characterized by stiffening and convulsing. The estimated number of Illinoisans suffering from tonic-clonic seizures is 35,000 children and adults.

Sudden Unexpected Death in Epilepsy, or SUDEP, occurs in approximately 1.2 out of every 1,000 children and adults with epilepsy each year. Tonic-clonic seizures, especially those occurring at night, are the strongest known risk factors for SUDEP. The number one protective factor for SUDEP is early intervention during a seizure.

FDA- cleared seizure monitoring and detection devices detect seizures in real time, alerting caregivers to intervene, reducing the cost of hospitalization and emergency room visits, and most importantly, saving lives. The devices are primarily geared toward tonic-clonic seizures. They offer a proven, cost-effective method to reduce mortality, prevent hospitalizations, relieve mental health issues, and improve quality of life. The cost of the devices range from \$250 for wearable detectors to \$500 for bed based monitors and \$1,000 for advanced multi-sensory systems.

Illinois has an opportunity to be a national leader in helping to save lives for people with epilepsy, which affects 1 in 26 Americans and is the fourth most common neurological disorder:

- The risk of SUDEP can be reduced with intervention during a seizure;
- Seizure detection and monitoring devices save lives;
- The cost of detection and monitoring devices is minimal compared to the cost of Emergency Room visits and hospitalizations, or the devastating toll of SUDEP;
- Families and caregivers experience profound improvements in safety, sleep, and quality of life;
- Doctors obtain critical seizure tracking data to improve quality and precision of care;
- Insurance providers will save money long-term.

For these reasons, the Illinois Epilepsy community respectfully asks for your support of SB 2762.

SENATE BILL 2762

THIS BILL HAS THE SUPPORT OF THE ADVOCACY ORGANIZATIONS LISTED ABOVE, AS WELL LEADING EPILEPSY DOCTORS WITHIN THE STATE OF ILLINOIS, INCLUDING:

- **Dr. Stephan Schuele**
 - Medical Director
 - Northwestern Medicine Comprehensive Epilepsy Center
- **Dr. Jeff Loeb**
 - Head of neurology and rehabilitation
 - UIC College of Medicine
- **Dr. Adriana Bermeo-Ovalle**
 - Director of the EEG lab.
 - Rush University Medical Center
- **Dr. Rebecca Garcia-Sosa**
 - Attending Physician, Division of Neurology, Epilepsy Center
 - Ann & Robert H. Lurie Children's Hospital of Chicago
- **Dr. Jorge Asconape**
 - Fellowship Director, Clinical Neurophysiology
 - Loyola Medicine
- **Dr. Douglas R. Nordli, Jr.**
 - Professor of Pediatrics and Neuroscience Institute; Chief, Section of Pediatric Neurology; Co-Director, Comprehensive Epilepsy Center
 - UChicago Medicine
- **Dr. Takijah Heard**
 - Director, Pediatric Neurophysiology
 - Asst Prof University of Chicago Pritzker School of Medicine
 - Endeavor Health